60 Degrees Pharmaceuticals, Inc. SXTP 深 沪
等待开盘 06-30 09:30:00 美东时间
1.78
+0.170
+10.56%
华盛通- 最 高1.89
- 今 开1.60
- 成交量 15.97万股
- 最 低 1.57
- 昨 收 1.61
- 总市值 473.35万
- 52周最高 10.7712
- 市盈率 静 --
- 换手率 6.00%
- 52周最低 1.22
- 委 比 -75.09%
- 总股本 265.93万
- 历史最高 2076.00
- 量 比 3.55
- 振 幅 19.88%
- 历史最低 1.36
- 每 手 1
- 风险率 2.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多60 Degrees Pharma Executes Patent Licensing Agreement With Florida State University To Commence Large-Scale Production Techniques To Extract, Purify Castanospermine From Seeds Of Australian Chestnut For Non-Prescription Uses
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to...
06-11 20:13
60 Degrees Pharmaceuticals Says Co. May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001946563/000121390026064796/ea0293532-8k_60degrees.htm
06-04 05:08
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3.7
Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $4.2 to $3.7.
05-22 19:56
HC Wainwright & Co. Downgrades 60 Degrees to Neutral
HC Wainwright & Co. analyst Matthew Keller downgrades 60 Degrees (NASDAQ:SXTP) from Buy to Neutral.
05-21 01:03
60 Degrees Q1 EPS $(1.28) Misses $(0.76) Estimate, Sales $76.377K Miss $435.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.76) by 68.42 percent. This is a 79.52 percent increase over losses of $(6.25) per share from the
05-15 21:29
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $4.2
Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $11.2 to $4.2.
04-09 19:43
60 Degrees Pharmaceuticals shares are trading higher. The company reported its Q4 financial results.
60 Degrees Pharmaceuticals shares are trading higher. The company reported its ...
03-31 23:46
60 Degrees Q4 EPS $(1.47) Misses $(1.12) Estimate, Sales $303.385K Miss $400.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.12) by 31.25 percent. This is a 97.41 percent increase over losses of $(56.80) per share from the
03-31 19:50
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification With FDA For Australian Chestnut Extract; Inks Deal To License Florida State University's Ownership Rights To New Capsule Formulation Methods For Australian Chestnut Extract
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it submitted a
03-18 20:10
